It is important to note that the proposed therapeutic blockade of the Gal-9/Tim-3 axis in SLE appears to contradict its anti-inflammatory roles observed in conditions like psoriasis or HSV infection (sections below). This evidence concerns the gene HAVCR2 and systemic lupus erythematosus.